ArticleInsights into imaging2026
Radiological pure-solid appearance clinical stage I lung adenocarcinoma: a comparative study of mucinous and non-mucinous adenocarcinoma based on imaging features and survival outcomes.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesOur study aims to compare the clinicopathological, genetic, and prognostic differences between pure-solid appearance clinical stage I mucinous and non-mucinous adenocarcinomas. MATERIALS AND
methodsFive hundred seventy-nine patients with radiological pure-solid appearance clinical stage I lung adenocarcinoma, were retrospectively evaluated. Clinicopathological, radiological, genetic characteristics, and recurrence patterns were compared between the non-mucinous adenocarcinoma and mucinous adenocarcinoma groups. Recurrence-free survival (RFS) and overall survival (OS) were assessed by Kaplan-Meier curves and compared between groups using log-rank tests. Cox proportional hazard models were used to analyze prognostic factors.
resultsOf 579 patients (mean age, 59.9 years ± 9.7 [SD]; 298 women), 442 had non-mucinous adenocarcinoma, and 137 had mucinous adenocarcinoma. The non-mucinous adenocarcinoma group, in comparison with mucinous adenocarcinoma, showed higher CEA levels (p = 0.003), higher CT values (36.88 vs 20.89 HU, p < 0.001), a higher incidence of emphysema (25.1% vs 3.6%, p < 0.001), a lower clinical T stage (51.8% vs 42.3%, p < 0.001), and the absence of air bronchogram (61.3% vs 27%, p < 0.001). Recurrences occurred more frequently in the non-mucinous adenocarcinoma group (38.5%, 170/442) compared to the mucinous adenocarcinoma group (13.1%, 18/137; p < 0.001). Brain metastasis was significantly more common in the non-mucinous adenocarcinoma group (27.1% vs 0%; p = 0.024). Compared with the non-mucinous adenocarcinoma group, the mucinous adenocarcinoma group had better 5-year RFS (86.9% vs 62.7%; p < 0.001) and 5-year OS (97.1% vs 83.2%, p < 0.001).
conclusionImaging features, survival outcomes, and recurrence patterns differed significantly between mucinous and non-mucinous lung adenocarcinomas. KEY POINTS: Question For radiological pure-solid appearance clinical stage I lung adenocarcinoma, there remains controversy regarding the clinicopathological characteristics and prognosis of mucinous versus non-mucinous subtypes. Findings There were significant differences in clinicopathological features, imaging findings, and recurrence patterns between mucinous and non-mucinous adenocarcinomas. Compared with the non-mucinous adenocarcinoma, the mucinous group had better 5-year RFS and 5-year OS. Critical relevance statement Lung mucinous adenocarcinoma, Lung mucinous adenocarcinoma, due to its unique imaging and clinicopathological features, was a special independent subtype of adenocarcinoma. For radiological pure-solid appearance lung adenocarcinoma, mucinous adenocarcinoma had a better survival prognosis than non-mucinous adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.